Maven exits Westfield Medical generating a 2.2x return

Share on:  

Maven has completed a profitable exit from Westfield Medical Group (Westfield). The trade sale to France domiciled Sterimed Group has generated a 2.2x blended return for investors.

Published: Dec 20, 2021
Focus: Private Equity

Westfield is one of the UK’s leading providers of single use sterilisation barrier packaging and other sterilisation products to the public and private healthcare and industrial sectors. Its customers include NHS hospital sterile departments, private hospitals, industrial and medical device manufacturers.

Maven led the management buyout of Westfield in 2016, funded through Maven’s co-investment network for professional clients ‘Maven Investor Partners’. With the investment and support provided by Maven, the business has expanded in the UK and grown its international footprint, with sales into EMEA, Asia and the Americas accounting for over 45% of 2020 revenues.

Under the stewardship of CEO James Vero, Somerset-based Westfield has established an excellent reputation for innovation, quality and service, providing a comprehensive range of products which are vital for creating sterile environments in the healthcare and specialist manufacturing sectors.


“The sale of Westfield represents a good return for our investors. The management team have been instrumental in successfully delivering the organic growth plan in recent years and the business has performed strongly. The sale to the Sterimed Group is a great strategic fit for Westfield with significant opportunities for the two businesses to explore. It has been a pleasure to work with the Westfield management team and we wish them well as the company embarks on the next stage of its growth."

Tom Purkis, Partner at Maven


“We have grown the business organically in recent years to become one of the market leaders in the sterile barrier market. We have welcomed Maven’s strategic support and guidance throughout the latest phase of Westfield’s evolution. It has been a very exciting period and now we remain focussed on the opportunities ahead with the Sterimed Group.”

James Vero, CEO at Westfield


Posted in:
Private Equity

Subscribe for email updates